-
Antiviral API
- Arenavirus
- Cytomegalovirus (CMV)
- Dengue virus
- Endogenous Metabolite
- Enterovirus (EV)
- Epstein-Barr virus (EBV)
- Filovirus
- Flavivirus
- HCV Protease
- Hepatitis B Virus (HBV)
- Hepatitis C Virus (HCV)
- Herpes simplex Virus (HSV)
- HIF/HIF Prolyl-Hydroxylase
- HIV Integrase
- HIV Protease
- Human immunodeficiency Virus (HIV)
- Human papillomavirus (HPV)
- Influenza Virus
- Nipah virus
- Orthopoxvirus
- Others
- Rabies virus (RABV)
- Respiratory syncytial Virus (RSV)
- Reverse Transcriptases (RTs)
- SARS-CoV
- Tobacco mosaic virus (TMV)
- Vesicular stomatitis virus (VSV)
- Virus Protease
- West Nile virus
- Antiviral intermediates
Oxethazaine
![{PARAM:[Name]}({[CAS]})](https://resource.bocsci.com/structure/126-27-2.gif)
| Category | Hepatitis B Virus (HBV) |
| CAS | 126-27-2 |
| Description | Oxethazaine, an effective topical anesthetic, could be used to relieve the pain caused by peptic ulcer disease and esophagitis. |
Product Information
| Synonyms | OXETHAZAINE;OXETHAZINE;OXETACAINE;2,2'-((2-hydroxyethyl)imino)bis(n-(1,1-dimethyl-2-phenylethyl)-n-methylaceta;2,2'-((2-hydroxyethyl)imino)bis(n-(alpha,alpha-dimethylphenethyl)-n-acetamid;2,2'-((2-hydroxyethyl)imino)bis(n-(alpha,alpha-dimethylphenethyl)- |
| IUPAC Name | 2-[2-hydroxyethyl-[2-[methyl-(2-methyl-1-phenylpropan-2-yl)amino]-2-oxoethyl]amino]-N-methyl-N-(2-methyl-1-phenylpropan-2-yl)acetamide |
| Molecular Weight | 467.65 |
| Molecular Formula | C28H41N3O3 |
| Canonical SMILES | CC(C)(CC1=CC=CC=C1)N(C)C(=O)CN(CCO)CC(=O)N(C)C(C)(C)CC2=CC=CC=C2 |
| InChI | InChI=1S/C28H41N3O3/c1-27(2,19-23-13-9-7-10-14-23)29(5)25(33)21-31(17-18-32)22-26(34)30(6)28(3,4)20-24-15-11-8-12-16-24/h7-16,32H,17-22H2,1-6H3 |
| InChIKey | FTLDJPRFCGDUFH-UHFFFAOYSA-N |
| Boiling Point | 630.4±55.0 °C at 760 mmHg |
| Melting Point | 104-105°C |
| Flash Point | 335.1±31.5 °C |
| Purity | 98% |
| Density | 1.093 g/cm3 |
| Solubility | Chloroform (Slightly), Methanol (Slightly) |
| Appearance | White powder. |
| Application | Oxethazaine is an effective topical anesthetic that could be used to relieve the pain caused by peptic ulcer disease and esophagitis. |
| Shelf Life | As supplied, 2 years from the QC date provided on the Certificate of Analysis, when stored properly |
| Storage | -20°C Freeze |
| Complexity | 585 |
| Exact Mass | 467.31479218 |
| Index Of Refraction | 1.558 |
| In Vivo | Oxetacaine (intraperitoneal injection; 5, 10, and 15 mg/kg; during days 4-11) doses induces significant conditioned place preference (CPP), and there are no differences among the groups. While its postive control group phentermine only 3 mg/kg causes significant CPP. |
| PSA | 64.09000 |
| Target | HBV |
| Vapor Pressure | 0.0±1.9 mmHg at 25°C |
| XLogP3-AA | 3.8 |